Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 9/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14480329 | 1.00 | MAPT (0.46) | MAPTCHRNA7ACACBFFAR1ITGB3 | |
| SCHEMBL14480190 | 1.00 | MAPT (0.46) | MAPTCHRNA7ACACBFFAR1ITGB3 | |
| SCHEMBL14549988 | 0.89 | CHRNA7 (0.37) | MAPTCHRNA7ACACBFFAR1ITGB3 | |
| SCHEMBL14480142 | 0.87 | ACACB (0.44) | MAPTCHRNA7ACACBFFAR1 | |
| SCHEMBL14549993 | 0.87 | CHRNA7 (0.46) | MAPTCHRNA7ACACBFFAR1ITGB3 | |
| SCHEMBL14480141 | 0.87 | ACACB (0.44) | MAPTCHRNA7ACACBFFAR1 | |
| SCHEMBL998123 | 0.85 | NNMT (0.45) | MAPTCHRNA7 | |
| SCHEMBL14480161 | 0.85 | NNMT (0.45) | MAPTCHRNA7 | |
| SCHEMBL998124 | 0.85 | NNMT (0.45) | MAPTCHRNA7 | |
| SCHEMBL14480351 | 0.82 | MAPT (0.41) | MAPTCHRNA7ACACBFFAR1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRM1, CHRM5 | MAPT 416/4885CHRNA7 1/4885ACACB 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.